CAS 86541-75-5

Benazepril

Description:

Benazepril is an angiotensin-converting enzyme (ACE) inhibitor primarily used in the treatment of hypertension and heart failure. It is a white to off-white crystalline powder that is soluble in water and exhibits a molecular formula that reflects its complex structure. Benazepril works by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. Its pharmacokinetics involve absorption after oral administration, with a prodrug form that is converted to its active metabolite, benazeprilat, in the liver. The substance has a relatively long half-life, allowing for once-daily dosing in clinical practice. Common side effects may include dizziness, cough, and elevated potassium levels, while serious adverse effects can involve renal impairment and angioedema. Benazepril is contraindicated in pregnancy due to potential harm to the fetus. Overall, it is a well-established medication in cardiovascular therapy, contributing to improved outcomes in patients with hypertension and related conditions.

Formula: C₂₄H₂₈N₂O₅

InChI: InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1

InChI key: InChIKey=XPCFTKFZXHTYIP-PMACEKPBSA-N

SMILES: C(C(O)=O)N1C=2C(CC[C@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)C1=O)=CC=CC2

Synonyms:

• (3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid
• 1H-1-Benzazepine-1-acetic acid, 3-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, (3S)-
• 1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [R-(R*,R*)]-
• 1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]-
• Benapril
• Briem
• Cibacen
• Cibacen WS
• Cibacene
• [(3R)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
• Benazepril

Benazepril Hydrochloride

CAS: 86541-74-4, 86541-75-5

Formula: C₂₄H₂₈N₂O₅·HCl

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Almost white powder to crystal

Molecular weight: 460.96

Ref: 3B-B3611

2-((S)-3-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid

CAS: 86541-75-5

2-((S)-3-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid

Purity: 99%

Molecular weight: 424.5g/mol

Ref: 54-OR1065549

Benazepril

CAS: 86541-75-5

Benazepril inhibits the activity of circulating angiotensin-converting enzyme (ACE) in horses.

Formula: C₂₄H₂₈N₂O₅

Color and Shape: Solid

Molecular weight: 424.49

Ref: TM-T20921

Benazepril

CAS: 86541-75-5

Benazepril is a drug that is used to treat hypertension and congestive heart failure. It is also used in the treatment of renal disease, diabetic nephropathy, and post-myocardial infarction syndrome. Benazepril inhibits angiotensin I-converting enzyme (ACE), an enzyme involved in the conversion of angiotensin I to angiotensin II. This leads to decreased activity of the renin-angiotensin system, which results in reduced blood pressure and vasodilation. Benazepril has been shown to have beneficial effects on cardiac remodelling and fibrosis due to its ability to inhibit injury caused by growth factor-β1. The low dose group had better outcomes than the high dose group with respect to cardiac effects, such as papillary muscle thickening and tubulointerstitial injury. These effects were reversed following discontinuation of benazepril therapy.

Formula: C₂₄H₂₈N₂O₅

Purity: Min. 95%

Molecular weight: 424.49 g/mol

Ref: 3D-FB171048